Form 4: Intra-Cellular Therapies Director Rory Riggs Acquires Shares
SEC Form 4 Filing
Director Rory Riggs acquired 246 shares of Intra-Cellular Therapies, Inc. at a price of $73.17 per share on September 30, 2024.
Summary
- On September 30, 2024, Rory Riggs, a director of Intra-Cellular Therapies, Inc., acquired 246 shares of common stock.
- The shares were purchased at a price of $73.17 per share.
- Following the transaction, Riggs directly owns 117,108 shares of Intra-Cellular Therapies, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a director purchasing shares, which can be seen as a mildly positive signal, but not significantly impactful.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.
Key Dates
| Date | Description |
|---|---|
| September 24, 2024 | Date of Power of Attorney execution. |
| September 30, 2024 | Date of stock acquisition. |
| October 02, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.